In short
This article examines the use of feladilimab, an innovative immunotherapy drug, in various clinical trials for cancer treatment. Feladilimab is being studied alone and in combination with other therapies for different types of cancer, including non-small cell lung cancer, head and neck cancer, and multiple myeloma. The trials aim to evaluate the safety, efficacy, and potential benefits of feladilimab in improving patient outcomes.
At a glance
- Drug Name
- Feladilimab (GSK3359609)
- Drug Type
- Humanized anti-ICOS agonist immunoglobulin G4 (IgG4) monoclonal antibody
- Administration
- Intravenous (IV) infusion, typically every 3 weeks
- Cancer Types Studied
- Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Multiple myeloma
- Combination Therapies
- Pembrolizumab, Ipilimumab, Chemotherapy regimens, Belantamab mafodotin
- Primary Outcomes
- Safety, tolerability, adverse events, dose-limiting toxicities
- Secondary Outcomes
- Overall survival, progression-free survival, objective response rate, duration of response
- Study Phases
- Phase I, II, and III trials
- Key Measurements
- Pharmacokinetics, pharmacodynamics, anti-drug antibodies, receptor occupancy
What is Feladilimab?
Feladilimab is an experimental drug being developed for the treatment of various types of cancer. It is also known by several other names, including GSK3359609 and EOS884448. Feladilimab belongs to a class of drugs called immunotherapy, which work by helping the body's immune system fight cancer cells.
This medication is not yet approved for general use and is currently being studied in clinical trials to determine its safety and effectiveness in treating different types of cancer.
How Does Feladilimab Work?
Feladilimab is a type of drug called a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens like cancer cells. Specifically, feladilimab is an anti-ICOS agonist antibody.
ICOS stands for Inducible T cell Co-Stimulator. It's a protein found on the surface of certain immune cells called T cells. By targeting and activating ICOS, feladilimab aims to boost the immune system's ability to recognize and attack cancer cells.
What Conditions Does Feladilimab Treat?
Feladilimab is being studied for the treatment of several types of cancer, including:
- Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer.
- Head and neck squamous cell carcinoma (HNSCC): This is a type of cancer that affects the mouth, nose, and throat.
- Multiple myeloma: A cancer of plasma cells, which are a type of white blood cell.
- Other advanced solid tumors: This refers to various types of cancers that form solid masses.
Clinical Trials and Research
Feladilimab is being studied in several clinical trials to evaluate its effectiveness and safety. These trials are testing feladilimab both as a single treatment and in combination with other cancer drugs. Some key points about the ongoing research include:
- Combination with other immunotherapy drugs: Feladilimab is being tested alongside drugs like pembrolizumab and ipilimumab, which are also immunotherapies.
- Combination with chemotherapy: Some trials are exploring how feladilimab works when given with standard chemotherapy drugs.
- Comparison to standard treatments: Researchers are comparing feladilimab to current standard-of-care treatments to see if it offers any advantages.
- Different dosing schedules: Various doses and treatment schedules are being tested to find the most effective and safe way to administer the drug.
Potential Side Effects
As with all medications, feladilimab can cause side effects. In clinical trials, researchers are carefully monitoring patients for any adverse reactions. Some potential side effects that have been observed include:
- Immune-related adverse events: Because feladilimab works by stimulating the immune system, it can sometimes cause the immune system to attack healthy tissues. This can lead to inflammation in various parts of the body.
- Infusion-related reactions: Some patients may experience reactions during or shortly after receiving the drug through an IV.
- Fatigue: Feeling very tired is a common side effect of many cancer treatments, including immunotherapies.
- Changes in blood tests: Feladilimab may affect various blood cell counts and other laboratory test results.
It's important to note that not all patients will experience these side effects, and the full range of potential side effects is still being studied in clinical trials.
Future Prospects
Feladilimab is still in the early stages of development, but researchers are hopeful about its potential. If the ongoing clinical trials show positive results, feladilimab could become a valuable new option for treating various types of cancer.
Some areas of particular interest for future research include:
- Identifying which patients are most likely to benefit from feladilimab treatment.
- Exploring additional combination treatments to enhance the effectiveness of feladilimab.
- Investigating feladilimab's potential in treating other types of cancer not currently being studied.
As research continues, we may learn more about how feladilimab can be used to help patients with various forms of cancer. Patients interested in learning more about feladilimab should speak with their healthcare provider about the latest developments and potential clinical trial opportunities.